Selective receptor antagonist to the human cytokine, type 1 interleukin-1 (IL-1)
Catalogue number crb1001289 Molecular Weight 1895.9 Sequence (one letter code) Ac-FEWTPGWYQJYALPL-amide Sequence (three letter code)
Aliase IL-1ra, Ac-FEWTPGWYQXYALPL-amide Modifications Where J is unnatural amino acid 2-azetidine-1-carboxylic acid Purity >95% cas 185413-30-3 Storage -20°C References
Yan et al (2017) Chronic pain and impaired glial glutamate transporter function in lupus-prone mice are ameliorated by blocking macrophage colony-stimulating factor-1 receptors. J. Neurochem. 140(6) 963 PMID: 28072466
Akeson et al (1996) AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J Biol. Chem. 271(48) 30517 PMID: 8940020
Manufactured in: United Kingdom
AF12198 is a selective receptor antagonist to the human cytokine, type 1 interleukin-1 (IL-1) and thus blocks IL-1β signalling. AF12198 can inhibit IL-1-induced IL-8 production by human dermal fibroblasts and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression by endothelial cells. AF12198 also blocks IL-1 induction of IL-6 and down regulates IL-6 induction in monkeys. AF12198 does not bind the human type II IL-1 receptor, or the murine type I IL-1 receptor.
IL-1 influences a wide range of immune and inflammatory responses. Sustained expression of even low levels of IL-1 can be harmful in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease